Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biogen Pharmachem Industries held its 30th Annual General Meeting on 25th September 2025 via video conferencing, lasting just 20 minutes (4:00 PM to 4:20 PM). Shareholders approved six resolutions, including adoption of audited financial statements for FY ended 31st March 2025 and re-appointment of the Statutory Auditor. A Special Resolution was passed appointing Mr. Kelash Bunkar (DIN: 10911360) as Wholetime Director and Chief Financial Officer, alongside the appointment of Mr. Aman Patel (DIN: 08483544) as Independent Director. Two additional Special Resolutions were approved to enhance the company's borrowing limits under Section 180(1)(c) and to permit investments, loans, guarantees and securities beyond the limits prescribed under Section 186 of the Companies Act, 2013. Voting results will be filed separately under Regulation 44(3).
The expanded borrowing and investment limits give the company greater financial flexibility to raise debt and deploy capital, which could signal upcoming growth or expansion plans. New board appointments strengthen the leadership team, though shareholders should await the detailed voting results to gauge actual support levels for each resolution.